What is a cannabis cultivation facility worth?

A cannabis production facility is unusual among businesses because the regulated asset that actually drives value — the federal licence — is tied to specific, security-cleared individuals rather than to the property itself. Two buildings that look identical from the parking lot can be worth very different amounts once the licence, the people named on it, and what it currently authorizes are taken into account.

The licence is the asset; the building is the shell

Licence class — cultivation, processing, or both — and the canopy or production capacity actually authorized under it set the real ceiling on what the operation can produce and sell. A larger building running below its authorized canopy, or holding a narrower licence class than its equipment suggests, is worth less to a buyer than a smaller facility operating fully within what it’s licensed to do.

Facility build quality against a moving security standard

Health Canada’s physical-security requirements — containment, HVAC, access control — have been updated over time, so a facility built to a since-superseded standard is a genuine discount even if it currently passes inspection, because the buyer effectively inherits the eventual upgrade cost. A facility built to the current standard carries the opposite: a real premium, because it defers that capital spend indefinitely.

Genetics and intellectual property

Established strains and genetics can be a genuinely separate, ownable asset, distinct from both the real estate and the licence, and buyers should apply the same intellectual property diligence rigour here as they would to any acquisition built around proprietary IP — confirming who actually owns it, not just who currently grows it.

Wholesale relationships as a concentration risk that shows up in price

Because finished cannabis can only be sold into the applicable provincial wholesale and distribution system — Ontario’s OCS is one example, and other provinces run their own equivalents — an operation’s standing relationship with that single buyer is closer to a single-customer contract than to a retail customer base. A buyer prices dependence on one legal channel the same way they would price any other single-customer concentration risk.

Why the transfer risk itself discounts the price

Because a change of control triggers a Health Canada review and requires the licence to be amended or reissued rather than simply following the sale, a buyer prices in the time and uncertainty of that process. Two otherwise identical facilities will not be worth the same to a buyer if one has cleaner, better-documented key-personnel and compliance records than the other — the paperwork itself is part of what’s being valued.

Getting a credible number

A defensible valuation calls for a business valuator with actual experience in a regulated, single-channel producer rather than a generalist, an appraisal grounded in what the licence authorizes rather than in square footage, and direct confirmation of current standing with Health Canada and the applicable provincial wholesaler before relying on any figure.

Why the buyer pool is narrower than the facility’s size suggests

A facility can be an attractive asset on paper and still have a genuinely small pool of buyers who can actually close on it, because closing depends on Health Canada clearing new principals before the licence can even be amended. In practice that pool tends to sort into three groups: other licensed producers consolidating capacity, vertically integrated cannabis companies folding cultivation into a business that already touches processing or retail, and well-capitalized entrants able to carry the facility through a slow, clearance-gated closing without the deal collapsing under its own timeline. A buyer who already holds a Health Canada licence, with principals already cleared on another facility, often represents a faster and more certain closing than a first-time entrant, even if the first-time entrant’s offer looks identical on price. A defensible valuation should reflect that a facility whose profile only really works for one of these three buyer types carries a real marketability discount relative to one that would suit all three, because the cost of a deal falling through at the clearance stage and needing to be remarketed is a genuine risk, not a formality.

Genetics as a value line separate from the licence

Proprietary strains and breeding lines are worth pulling apart from the licence value entirely, because unlike the licence they aren’t tied to specific cleared individuals and can, in principle, be assigned or licensed on their own terms. A facility with well-documented, provably owned genetics carries a value component that survives even a slow or uncertain licence-transfer process, which is part of why some transactions structure the intellectual property as a distinct schedule in the purchase agreement rather than folding it into one blended purchase price. The reverse is also true: genetics with unclear ownership — bred in-house without documentation, or originally sourced from a relationship that was never formalized — carry meaningfully more risk than their apparent quality suggests, and a buyer’s counsel should treat that gap the same way they would treat any other undocumented intellectual property asset in an acquisition.